MedicineAll countries · Checked
CagriSema (Novo Nordisk): Trial Results and FDA Decision Timeline
CagriSema is a once-weekly weight loss injection from Novo Nordisk that is not yet approved in the United States. The company expects an FDA decision in the fourth quarter of 2026. In its largest trial, adults lost an average of 20.4% of body weight over 68 weeks.
CagriSema at a glance
One weekly injection that combines semaglutide, the medicine in Wegovy, with cagrilintide. You cannot get it yet.
Where it standsUnder FDA review, decision expected Q4 2026
Biggest trial result−20.4% in 68 weeks
US launch planEarly 2027, if approved
Based on Novo Nordisk's Q3 2026 report. With no approval yet, there is no approved dose or price.
Want to know what the medicines you can get today cost?
Compare GLP-1 prices by countryOnly need one medicine? Open Wegovy price by country.
What it isFDA decisionResultsvs WegovySide effectsDosePriceWhat is nextFAQ
What is CagriSema?
CagriSema is a fixed-dose combination of two medicines. Semaglutide is a GLP-1 drug, and cagrilintide copies amylin, a hormone that helps you feel full.
The name joins the start of cagrilintide with the end of semaglutide. It has no brand name yet.
It is being developed as a weekly injection under the skin. The semaglutide part is already sold on its own, and you can read about it in semaglutide for weight loss.
CagriSema FDA approval date
Novo Nordisk filed its US application for CagriSema 2.4 mg/2.4 mg on December 18, 2025. It is not approved in the United States as of November 20, 2026.
In its Q3 2026 report, the company lists the FDA decision for the fourth quarter of 2026. We update this page the day a decision is announced.
If it is approved, Novo plans a full US launch at the start of 2027. That is a company plan, not a set date.
CagriSema weight loss results
REDEFINE 1 was a phase 3 trial of 3,417 adults without diabetes who had obesity, or overweight with at least one weight-related condition. It ran for 68 weeks.
CagriSema−20.4%Placebo−3.0%Difference−17.3 pts
That average counts everyone, including people who stopped treatment. Among people who stayed on the medicine, the average was −22.7% on CagriSema and −2.3% on placebo.
In a later analysis, people who lost at least 5% by week 8 lost 25.4% by week 68. The company calls this finding hypothesis-generating, so it does not predict your own result.
REDEFINE 9 tested a lower dose of 1.0 mg/1.0 mg. Novo reports 21% weight loss at 68 weeks.
REDEFINE 2 followed 1,206 adults with type 2 diabetes and overweight or obesity for 68 weeks, also against placebo.
All of these are trial averages, and everyone also had lifestyle support.
CagriSema vs Wegovy
Wegovy contains semaglutide alone. CagriSema adds cagrilintide to it. You can read about the approved version in Wegovy for weight loss.
For a medicine already on the market that works on two hormones, see Mounjaro (tirzepatide).
CagriSema side effects
In REDEFINE 1, stomach and gut side effects affected 79.6% on CagriSema and 39.9% on placebo.
REDEFINE 1 side effects (CagriSema / placebo)
Nausea55.0% / 12.6%
Constipation30.7% / 11.6%
Vomiting26.1% / 4.1%
Stopped because of side effects5.9% / 3.5%
These are trial figures. An approved label with its own frequency table does not exist yet.
CagriSema dose
There is no approved dose and no approved step-up schedule yet.
The target dose in REDEFINE 1 was 2.4 mg of cagrilintide plus 2.4 mg of semaglutide once a week.
Trial doses are not a dosing instruction. To see how approved GLP-1 medicines step up, use the GLP-1 dose schedule tool.
CagriSema price
With no approval, there is no price, and none is quoted here.
To compare what approved medicines cost today, open GLP-1 price by country or run your own numbers in the GLP-1 cost calculator.
CagriSema generic and what comes next
There is no generic, because there is no approved original yet. Which GLP-1 medicines have generics is answered in generic GLP-1 medicines.
Next dates from Novo: the FDA decision in Q4 2026, REDEFINE 11 results in the first half of 2027, and results for a higher dose, CagriSema HD, in the first half of 2028.
Other medicines in development are tracked in new GLP-1 drugs, including eloralintide and amycretin and survodutide.
CagriSema FAQ
Is CagriSema approved?
No. As of November 20, 2026 it is not approved in the US, and the FDA decision is expected in Q4 2026.
When will CagriSema be available?
If it is approved, Novo plans a US launch in early 2027. Other countries have no announced dates.
How much weight do people lose on CagriSema?
An average of 20.4% in 68 weeks in the largest trial, against 3.0% on placebo. Your result may be higher or lower.
Is CagriSema the same as Wegovy?
No. Wegovy has semaglutide only. CagriSema also has cagrilintide.
Can I buy CagriSema now?
No. There is no approved product, so nothing legitimate can be prescribed yet.
Keep reading
Wegovy (semaglutide) for weight loss
Mounjaro (tirzepatide) by country
This page follows Novo Nordisk's official announcements and trial records and is updated when they change. See how we check our pages.
Update log
: First published.
Sources
Novo Nordisk, CagriSema US FDA submission and REDEFINE 1 results (December 18, 2025).
Novo Nordisk, REDEFINE 1 post hoc analyses at ObesityWeek 2026 (November 15, 2026).
Novo Nordisk, Investor presentation Q3 2026.
Novo Nordisk US, CagriSema REDEFINE 1 analyses, citing Garvey et al., N Engl J Med 2025;393:635-647.
GLP1 Note is an independent information site. Which medicine suits you is for your prescriber to decide.